Medication info
Neurogabalin Capsule 50 Milligrams (Pregabalin)

Neurogabalin Capsule 50 Milligrams (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›50mg / 1 capsule
Manufacturer / importer
Mothers Pharmaceutical Co., Ltd.
Appearance
A hard capsule with a white powder, blue upper part, and white lower part
Packaging
30 capsules/bottle
Approval status
Active

MFDS item code 202003710 · Approved 2020.05.21 · Insurance code 622804420

Summary

Main use
Treatment of neuropathic pain and partial-onset seizures; treatment of fibromyalgia
Who takes it
Adults · Children
Adult dose
This drug is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and depending on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Because the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
Mothers Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and partial-onset seizures; treatment of fibromyalgia

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used for the treatment of peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for the control of partial seizures in patients with epilepsy, and is effective even in cases with secondary generalized symptoms. Finally, it also helps relieve pain in patients with fibromyalgia. In summary, this drug is effective for various neurological pain and seizure control.

How to take

Adult dose

This drug is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Depending on the response and tolerability of the individual patient, the dose may be increased to 300 mg/day after 1 week. If needed, it may subsequently be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and depending on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys unchanged. Because the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained from the above equation by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) / Total daily dose of pregabalin a / Administration regimen / Starting dose (mg/day) / Maximum dose (mg/day) ≥60 / 150 / 600 / BID or TID ≥30-<60 / 75 / 300 / BID or TID ≥15-<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified under the administration regimen. b: The supplemental dose refers to a dose administered as a single additional dose. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age and older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behaviors, so if symptoms of depression or mood changes occur during treatment, you should inform your healthcare provider immediately. Individuals with an allergy to the ingredients of this medication or those with certain genetic conditions should not take it. Diabetic patients may need to adjust the dosage of blood sugar control medications due to weight gain. If symptoms of angioedema, such as swelling of the face or around the mouth, occur, the use of this medication should be stopped immediately. Elderly patients may experience dizziness or drowsiness when taking this medication and should be cautious of falls and other accidents; loss of consciousness or confusion may also occur. This medication can cause temporary blurred vision or changes in eyesight, which may improve upon discontinuation of the drug. Abruptly stopping this medication can result in withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so dosage should be reduced gradually in consultation with a healthcare provider. Patients with a history of substance abuse are at a higher risk for misuse of this medication, so they should take it cautiously and be monitored for signs of abuse. Patients with reduced kidney function may require dose adjustments. Patients with severe heart disease should exercise caution when taking this medication. Taking this medication in conjunction with other central nervous system depressants or opioid analgesics may increase the risk of respiratory depression. Pregnant women should avoid this medication during early pregnancy due to the risk of fetal malformations, and women of childbearing age should use effective contraception. Breastfeeding women should discuss with their healthcare provider whether to discontinue breastfeeding or the medication, as it can pass into breast milk. This drug can cause dizziness and drowsiness, so it is advised to avoid driving or operating hazardous machinery after taking it. Severe skin reactions may occur rarely, so if symptoms such as skin rashes, blisters, or mucosal damage occur, use should be discontinued immediately and healthcare providers should be notified. In case of overdose, confusion, drowsiness, depression, or seizures may occur, and appropriate medical treatment should be sought immediately.

Side effects

  • Suicidal thoughts
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral swelling
  • upper airway swelling
  • dizziness
  • drowsiness
Show 176 more
  • loss of consciousness
  • confusion
  • mental disorders
  • blurred vision
  • vision changes
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • sweating
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • decreased appetite
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • euphoria
  • decreased libido
  • depersonalization
  • hyperesthesia
  • agitation
  • mood swings
  • emotional blunting
  • mood elevation
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attacks
  • impulsivity
  • apathy
  • ataxia
  • motor coordination disorders
  • equilibrium disorders
  • amnesia
  • attention disturbances
  • memory impairment
  • trembling
  • speech disorders
  • sensory disturbances
  • sensory impairment
  • sedation
  • drowsiness
  • cognitive impairment
  • nystagmus
  • language disorders
  • tonic-clonic seizures
  • reflex reduction
  • movement disorders
  • psychomotor agitation
  • positional dizziness
  • hypersensitivity
  • burning sensation
  • action tremor
  • syncope
  • confusion
  • decreased motor function
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • double vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • throat tightness
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory impairment
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • joint pain
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasms
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urination disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • breast discharge
  • breast enlargement
  • peripheral edema
  • edema
  • gait disturbances
  • falls
  • feeling intoxicated
  • altered perception
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased serum creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood glucose
  • decreased platelet count
  • decreased serum potassium
  • weight loss
  • increased serum creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • nausea
  • diarrhea
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • lethargy
  • delirium
  • paralysis (facial paralysis)
  • affective disorders
  • agitation
  • seizures
  • drowsiness
  • state of confusion
  • depression
  • restlessness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It's advisable to maintain the storage temperature between 15 to 30 degrees Celsius to preserve the medication's efficacy and safety over time.

Appearance and packaging

Appearance

A hard capsule with a white powder, blue upper part, and white lower part

Package unit

30 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.